Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.
A correlation between regulation of cell proliferation and polyamine metabolism is described. The latter can enter protein synthesis through the modification of eukaryotic initiation factor 5A (eIF5A) and the formation of the peculiar amino acid hypusine. Specific inhibitors of hypusine formation induce apoptosis that can be potentiated by the combination with cytokines such as interferonalpha (IFNalpha) that itself decreases hypusine synthesis. We have also demonstrated that the concomitant treatment of cancer cells with IFNalpha and the protein synthesis inhibitor fusion protein TGFalpha/Pseudomonas Aeruginosa toxin synergize in inducing cancer cell growth inhibition. Another way used by polyamines to induce apoptosis is the generation of intracellular oxidative stress through the interaction with bovine serum amine oxidase (BSAO). This enzyme used simultaneously to spermine induces apoptosis, necrosis, inhibition of cell proliferation and inhibition of DNA and protein synthesis in several cell types. The enzymatic oxidation products of polyamine, H2O2 and aldehyde(s) cause these effects. We have recently found that the cytotoxicity of anti-cancer agents, either etoposide or docetaxel, in cancer cells is potentiated in the presence of BSAO/Spermine. In conclusion, polyamine metabolites could be useful in the design of new therapeutic strategies.
Marra
M
M
Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours Fondaz. G. Pascale, Naples, Italy.
Agostinelli
E
E
Tempera
G
G
Lombardi
A
A
Meo
G
G
Budillon
A
A
Abbruzzese
A
A
Giuberti
G
G
Caraglia
M
M
D012437:Adenosylmethionine Decarboxylase / Q000378:metabolism; D006631:Amine Oxidase (Copper-Containing) / Q000502:physiology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D020169:Caspases / Q000378:metabolism; D002417:Cattle; D049109:Cell Proliferation / Q000187:drug effects*; D000077143:Docetaxel; D004357:Drug Synergism; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D006979:Hyperthermia, Induced; D016898:Interferon-alpha / Q000502:physiology; D008239:Lysine / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000494:pharmacology; D009955:Ornithine Decarboxylase / Q000378:metabolism; D010084:Oxidation-Reduction; D010448:Peptide Initiation Factors / Q000502:physiology; D011073:Polyamines / Q000378:metabolism*; D016601:RNA-Binding Proteins / Q000502:physiology; D043823:Taxoids / Q000494:pharmacology; D000097574:Eukaryotic Translation Initiation Factor 5A
D012437:Adenosylmethionine Decarboxylase; D006631:Amine Oxidase (Copper-Containing); D000970:Antineoplastic Agents; D020169:Caspases; D000077143:Docetaxel; D005047:Etoposide; D016898:Interferon-alpha; D008239:Lysine; D009955:Ornithine Decarboxylase; D010448:Peptide Initiation Factors; D011073:Polyamines; D016601:RNA-Binding Proteins; D043823:Taxoids; D000097574:Eukaryotic Translation Initiation Factor 5A; C100028:hypusine